Why AI Startups Are Avoiding IPOs
Listen to the audio version of this article (generated by AI).
Michael’s note: Most investors assume the biggest tech fortunes are made in the stock market.
But InvestorPlace’s top tech analyst, Luke Lango, believes AI has flipped the script.
According to Luke, a whole class of private AI startups is in the crosshairs of big tech. And for the first time, everyday investors can buy in before they get bought up.
With this comes the potential to turn small stakes – as little as $500 – into windfall profits.
He shared his full framework for finding the best deals – and one specific opportunity – during the 2026 AI Megadeal Event. And if you were among the 4,370 investors tuned in to watch the live broadcast, you already know the private AI company Luke likened to a “Nvidia for robotics.”
But if you didn’t, don’t worry. For a limited time, Luke and his team are keeping the replay online. Watch it here now.
And read on to hear how another pioneering technology trend back in the ‘70s presents the perfect analog to AI investing today…
BY LUKE LANGO, SENIOR INVESTMENT ANALYST, INVESTORPLACE
In January 1976, two men met at a San Francisco bar to discuss a new idea.
One was the scientist Herbert Boyer, who had helped develop a method for cutting and recombining DNA – a technique that could, in theory, instruct living cells to produce proteins the human body needed but couldn’t manufacture on its own.
The other man was a 28-year-old venture capitalist named Robert Swanson, who believed this discovery could become the foundation of an entirely new kind of medicine. Instead of synthesizing compounds in a lab, you could engineer cells to produce drugs that had never existed before.
Boyer had initially agreed to give Swanson 10 minutes.
Ten minutes became several hours and a few beers. By the end of the conversation, they had agreed to start a company together.
They called it Genentech – short for “genetic engineering technology.”
Four years later, Genentech went public. Biotechnology barely existed as an industry. The company had not yet won approval for a single medicine. The entire premise – that you could reliably program living organisms to manufacture drugs – had not yet been commercially proven.
Investors rushed in anyway. Genentech offered 1 million shares at $35. Within the first hour, the price climbed to $88. It closed the day at $71.25 – a 104% gain before the company had sold a single FDA-approved product.
Those investors clearly understood that they were early. The entire commercial promise of biotechnology still lay ahead. The stock market was opening a door to an industry in its infancy, and investors could walk through it.
That was 1980. The AI boom of 2026 is operating by completely different rules.
In this piece, I’m going to show you how those rules have changed, why it matters enormously for your money, and what I believe you can do about it right now.
Stay with me. This may be the most important shift in technology investing…
When the Stock Market Used to Arrive First
Genentech’s story was not unusual for its era. It was the norm.
Microsoft (MSFT), Amazon (AMZN), and Nvidia (NVDA) all reached the stock market while their biggest growth stories were still largely ahead of them. Buying after they got there still meant getting in early.
In each case, the stock market arrived while the story was still young. The company had proven enough to attract public investors, but most of the growth remained ahead. The opening bell was an invitation to join a journey that had barely begun.
The AI economy works differently.
Many AI companies follow a different path. OpenAI is worth hundreds of billions of dollars without ever going public. Anthropic may reach a trillion-dollar valuation before it goes public. Even SpaceX (SPCX) spent decades creating value before Wall Street ever had a chance to participate.
The pattern is not a coincidence. It is a consequence of how the technology industry changed.
Why the Greatest AI Companies Can Afford to Wait
Young companies once needed Wall Street. Going public gave them access to capital they couldn’t raise any other way – money to hire engineers, build infrastructure, and scale operations before revenue could fund the growth themselves.
Today’s most ambitious AI companies don’t have that problem.
Deep-pocketed funders funnel hundreds of billions of dollars into AI companies that aren’t listed on the stock market. OpenAI raised $122 billion in a single funding round. Anthropic raised billions from Amazon and Alphabet (GOOGL) before its IPO was anywhere in sight. The capital that once required the stock market is now available without it.
The stock market still brings money. But it also brings quarterly earnings pressure, extensive regulations, activist shareholders, and constant public scrutiny. If a company can fund its growth without accepting those obligations, its founders may decide there is no reason to hurry.
AI creates one more reason to wait: the acquisition offer.
The largest technology companies are racing to secure models, data, energy, robotics, security, and specialized talent. When a young company solves a problem that one of those giants considers urgent, it may receive an acquisition offer long before the stock market becomes necessary.
In that case, the stock market doesn’t arrive late. It never arrives at all.
While early investors still get paid, and the company still creates enormous value, ordinary investors never get the chance to participate.
Two Timelines, One AI Boom
This has produced something unusual: two completely separate AI investment timelines running simultaneously.
The first timeline plays out in public. Nvidia reports record chip demand. Microsoft announces a new data center. Google releases a new model. Investors can watch these developments unfold in real time and make decisions accordingly.
The second timeline is almost invisible. It starts when a small team solves a problem no one else has solved. By the time Wall Street hears about it, the earliest investors have already captured much of the upside.
Genentech’s public investors got in before biotechnology had proven it could work at scale. They were early enough that decades of value creation still lay ahead of them.
Today, the equivalent moment increasingly happens before the stock market ever gets involved.
That is the shift. And for most investors, it has meant watching the AI boom’s biggest fortunes be created in rooms they were never invited into.
The Lock Is Starting to Come Off
For most of recent history, there was no legitimate answer to this problem for ordinary investors.
That is beginning to change – not completely, and not without limits, but in ways that matter.
I am not going to lay out the full mechanics here, because I walk through exactly how this works in my 2026 AI Megadeal Event. What I will tell you is that certain developments in recent years have created pathways that genuinely did not exist before. There are ways for individual investors to evaluate opportunities that would previously have been unavailable to them.
I have spent the past year applying a disciplined framework to these opportunities. I call it PPT.
People: Are the founders the kind of people who figure things out when everything goes wrong? Do they have the technical depth, the relationships, and the resilience to build something real?
Product: Does it solve a genuine, urgent, expensive problem, or is it a thin marketing layer built on someone else’s technology? Are customers actually paying for it, or just saying they’re interested?
Timing: Is the market ready for this right now? Is this company in the direct path of the capital and attention currently flooding the AI economy, or is it a decade too early?
Early-stage companies fail. The goal of PPT isn’t to eliminate risk. It’s to evaluate it with the same discipline successful early investors have always used.
I have found one AI company that passes this filter today. It’s not on the stock market. It is operating in a category where the largest technology companies in the world are spending aggressively, and it is solving a problem they have not yet solved themselves.
It represents the kind of early opportunity that Genentech’s 1980 investors had – a company where most of the defining growth chapter still lies ahead.
I shared everything about it – the company, my PPT analysis, and exactly how you can access it – during my free 2026 AI Megadeal Event. You can watch it here now.
Robert Swanson walked into a bar in 1976 with a theory and walked out with the beginnings of an industry. The investors who got truly rich from what he built got in early.
The AI boom is producing the same dynamic, at a scale that dwarfs anything biotechnology ever created… but it’s doing so without the stock market.
Here’s the link again to the 2026 AI Megadeal Event replay.
Sincerely,
Luke Lango
Senior Investment Analyst, InvestorPlace